A Review of Current Concepts In Cancer Chemotherapy
DOI:
https://doi.org/10.32635/2176-9745.RBC.1986v32n1.3235Palavras-chave:
Tratamento Farmacológico, Neoplasias/terapia, Neoplasias/prevenção & controle, AntineoplásicosResumo
Chemotherapy today is a modality predominantly used to treat metastatic or disseminated malignant neoplastic disease. Depending upon the primary site and stage (extent) of disease, chemotherapy can be geared to be curative or palliative in its intent. Chemotherapy can lead to prolonged disease-free survival in a percentage of patients with certain stages of eieven different malignancies (Table 1). For some of these, chemotherapy can eradicate all malignancy by itself in advanced stages when macroscopic metastatic disease is present. For the three pediatric solid tumors on the list, chemotherapy is used as an adjuvant to surgery and/or irradiation to eradicate microscopic metastatic disease after the local modalities have removed or abiated the primary local and residual disease.
Downloads
Referências
Carter SK, Bakowski M and Hellman K. Chemotherapy of cancer, second edition, John Wiley and Sons, New York, 1981: 379.
Osterlind M et al: Continuous vs alternating combination chemotherapy for advanced small cell carcinoma of the lung. Ca Res 1983; 43: 6685-6689.
Carter SK and Livingston RB. Principies of cancer chemotherapy. In Carter SK, Qaststein E and Livingston RB: Principles of cancer treatment Mc Graw-HilI, New York, 1982; 95-111.
Bitran JD et al. Combined modality therapy for stage III non-oat cell bronchogenic carcinoma. Ca treat Rep 1973; 62: 327.
Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 1973; 4:31.
Green RA etal. Alkylatingagentsin bronchogenic carcinoma. Ca Treat Rep 1977; 61:347.
Edmonson JH et al. Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung. Ca Treat Rep 1976; 60: 925.
Hansen H et al. A combination of 3 and 4 drug combination chemotherapy for advanced small cell anaplastic carcinoma of the lung. Proc AACM-ASCO 1976; 17:129.
Cohen MH et al. Intensive chemotherapy of small cell bronchogenic carcinoma. Ca Treat Rep 1977; 61:349.
Hansen H et al. Treatment of small cell anaplastic carcinoma of the lung with an oral solution of VP16-213 (NSC 141 540) a phase II trial. Proc AACR-ASCO 1976: 17:129.
Cohen H et al. Cyclic alternating combination chemotherapy of small cell bronchogenic carcinoma. Proc AACR-ASCO 1978: 19: 359.
Livingston RB et al. Small cell carcinoma of lung: combined chemotherapy and radiation. Ann Int Med 1978: 88: 194. DOI: https://doi.org/10.7326/0003-4819-88-2-194
Hilton G. The present position relating to cancer of the lung. Results with radiotherapy alone. Thoráx 1960; 15: 17-18.
Klastersky J and Sculier JP. Chemotherapy of non-small cell lung cancer. Semim One 1 985; 12:38-48.
Gralle RJ et al. Cisplatin + Bindescrine combination chemotherapy for advanced carcinoma of the lung:; a randomized trial investigating two dosage schedules. Ann Int Med 1981; 95: 414-420. DOI: https://doi.org/10.7326/0003-4819-95-4-414
Gastro intestinal: Tumor Study Group. Adjuvant therapy of colon cancer. Results of a prospectively randomized trial. N EngI J Med 1984; 310: 737-743. DOI: https://doi.org/10.1056/NEJM198403223101201
Higgins GA et al. Adjuvant to Surgery in carcinoma of the lung. Arch Surg 1971; 102: 339. DOI: https://doi.org/10.1001/archsurg.1971.01350040101020
Higgins GA. Chemotherapy adjuvant to surgery for advanced surgery for gastrointestinal cancer. Clin Gastrointest 1976; 5:785. DOI: https://doi.org/10.1016/S0300-5089(21)00320-5
Dwight RW et al. FUDR as an adjuvant to surgery in cancer of the large bowel. J Surg Oncol 1973; 5:243. DOI: https://doi.org/10.1002/jso.2930050307
Lawrence W et al. Chemotherapy as an adjuvant to surgery for colorectal cancers. A follow-up report. Arch Surg 1978; 113:164. DOI: https://doi.org/10.1001/archsurg.1978.01370140054011
Grage TB et al. Adjuvant chemotherapy in large bowel câncer: demonstration of effectiveness of single agent chemotherapy in a prospectively controlled randomized trial. Recent Results Cancer Res 1979; 68:222. DOI: https://doi.org/10.1007/978-3-642-81332-0_34
Grage TB et al. Adjuvant chemotherapy with 5-Fluorouracil after surgical resection of colorectal carcinoma (C.O.G. protocol 7041), preliminary report. Am J Surg 1977; 133:59. DOI: https://doi.org/10.1016/0002-9610(77)90194-5
Grosse CE et al. Intraluminal 5-Fluorouracil chemotherapy adjuvant to surgical procedures for ressectable carcinoma of the colon and rectum Surg Gynecol Obstet 1977; 145:549.
Machover D et al. Treatment of advanced colorectal and gastric adenocardnomas with 5-Fu combined with high dose fóíic acid: a pilot study. Cancer treat Rep 1982; 66: 1803-09.
Byrne P et al. 5-Fluorouracil and higher dose folic acid treatment of colorectal carcinoma patients. Proc Am Soc Clin One 1983; 2:121. Abst C-474.
Cantrell JE et al. Phase II study of sequential methotrexate 5-Fu therapy in advanced measurable colorectal cancer. Cancer Treat Rep 1982; 66: 1563-65.
Ensminger W et al. Effective control of llver metastases from colon câncer with an implanted system for hepatic arterial chemotherapy. Proc Am S Clin One 1983; 2:123. Alast C-479.
Grage TB et al. Eur J Cancer 1979; 5:116.
Kemeny N et al. Update of randomized study of intrahepatic (H) vs systemic (S) infusion of Flourodeoxyuridine (FUDR) in patients with liver metastases from colorectal carcinoma (CRC). ASCO 1986; 5: Abstract 251.
Brinkly DN et al. Long term survival of women with breast cancer. Lancet 1984; 1:1118. DOI: https://doi.org/10.1016/S0140-6736(84)92525-X
Schottenfield D et al. Ten year results of the treatment of primary operable breast cancer. Cancer 1976; 38: 1001-1007. DOI: https://doi.org/10.1002/1097-0142(197608)38:2<1001::AID-CNCR2820380252>3.0.CO;2-5
Valagussa P et al. Patterns of relapse and survival following radical mastectomy. Cancer 1978; 41: 1170-1178. DOI: https://doi.org/10.1002/1097-0142(197803)41:3<1170::AID-CNCR2820410355>3.0.CO;2-I
Diahwe V et al. Ten year follow-up results of patients with carcinoma of the breast in a cooperativa Chemical trial evaluating surgical adjuvant chemotherapy. Surg Gyn Obstet 1975; 140: 528-534.
Cooke T et al. Oestrogen receptors in early breast cancer. Lancet 1979; V 1:995-997. DOI: https://doi.org/10.1016/S0140-6736(79)92752-1
Canellos GP et al. Combination chemotherapy for metastatic breast carcinoma. Cancer 1976; 38: 1882-1886. DOI: https://doi.org/10.1002/1097-0142(197611)38:5<1882::AID-CNCR2820380503>3.0.CO;2-H
Rossi A et al. CMF adjuvant program for breast cancer. Five year results. Proc AACR and Asco 1980; 21: Abst 336-404.
UK Breast Câncer Trials. Review of mortality results in randomized trials in early breast cancer. Lancet 1984; 2:1 204.
Hoffman K et al. CALGB retrospectiva analysis of toxicities in patients receiving adjuvant chemotherapy for stage II breast adenocarcinoma with either CMF or CMFVP. ASCO 1986; 65: 5. Abst 251.
Delena M et al. Combined chemotherapy radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemoth Pharmacol 1978; 1:53-59. DOI: https://doi.org/10.1007/BF00253147
Mourodson HT et al. Evaluation of single-drug versus multiple drug chemotherapy in the treatment of advanced breast cancer. Cancer Treat Rep 1977; 61:47-50.
Smalley AV et al. A comparison of Cyclophosphamide, Adriamycin, 5-Fluorouracil (CAF) and Cyclophosphamide, Methotrexate, 5-Fluorouracil, Vincristine, Prendnisone (CMFVP) in patients with metastatic breast cancer. Cancer 1977; 40625-632. DOI: https://doi.org/10.1002/1097-0142(197708)40:2<625::AID-CNCR2820400206>3.0.CO;2-M
BulI JM et al. A randomized comparative trial of Adriamycin versus Methotrexate in combination drug therapy. Cancer 1978;41:1649-1657. DOI: https://doi.org/10.1002/1097-0142(197805)41:5<1649::AID-CNCR2820410501>3.0.CO;2-J
Cummings F et al. Comparison of CAF versus CMFP in metastatic breast cancer; analysis of prognostic factors. J Qin One 1985; 16:932-940. DOI: https://doi.org/10.1200/JCO.1985.3.7.932
Allegra JC et al. Estrogen receptor Status. An importante variable in predicting response to endocrine therapy in metastatic breast cancer. Eur J Ca 1980; 16:323-331. DOI: https://doi.org/10.1016/0014-2964(80)90348-5
Kiang DT et al. Factors affecting estrogen receptors in breast cancer. Cancer 1977; 40: 1571-1576. DOI: https://doi.org/10.1002/1097-0142(197710)40:4<1571::AID-CNCR2820400429>3.0.CO;2-5
Allegra JC et al. Metastatic breast câncer. Preliminary results with oral hormonal therapy. Semin One 1985; 12:14)61-64.
Paterson HG et al. Response to treatment and its influence on survival in metastatic breast cancer. Am J Clin 1985; 8:283-292. DOI: https://doi.org/10.1097/00000421-198508000-00002
Young HH et al. Plasma testosterone leveis in patients with prostatic carcinoma before and after treatment. J Urol 1968: 99:788. DOI: https://doi.org/10.1016/S0022-5347(17)62795-2
Blackard CE et al. Orchiectomy for advanced prostatic carcinoma. Urology 1973; 1:553-560. DOI: https://doi.org/10.1016/0090-4295(73)90515-3
The Leuprolide Study Group Leuprolide versus Diethylstil-bestrol for metastic prostate cancer. New EngI Med 1984; 311:1281-1286. DOI: https://doi.org/10.1056/NEJM198411153112004
Young HH et al. Rasma testosterone leveis in patients with prostatic carcinoma before and after treatment. J Urol 1968; 1:553-560.
Torti FM et al. A randomized study of Doxorubicin versus Doxorubicin plus Cisplatin in endocrine — unresponsive metastatic prostatic carcinoma. Câncer 1985; 56: 2580-2586. DOI: https://doi.org/10.1002/1097-0142(19851201)56:11<2580::AID-CNCR2820561108>3.0.CO;2-W
Tannock IA. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate. J Qin One 1985; 3:1013-1021. DOI: https://doi.org/10.1200/JCO.1985.3.7.1013
GItstein E. Radiotherapy in Hodgkin's disease: achievements and future progress. Cancer 1977; 39:837-842. DOI: https://doi.org/10.1002/1097-0142(197702)39:2+<837::AID-CNCR2820390719>3.0.CO;2-F
Bonadonna G et al. Second International Conference on Malignant Lymphoma. Boston, Martins Nijhoff 1985.
Klino P and Connors JM. Proceedings of the Second Int Conf on Malignant Lymphoma, Lugano Switzerland. Boston, Martins Nijhoff 1985.
Santoro A et al. Salvage chemotherapy in relapsing Hodgkin's disease. Proc Am Soc Oin Oncol 1984; 3:995. Abst 995.
Bonadonna G et al. Third-time salvage chemotherapy in Hodgkin's disease. Semin Oncol 1985; 12:23-25. Supp 2.
Klino P and Connors JM. MACOP-B chemotherapy for the treatment of diffuse l large-cell lymphoma. Ann Int Med 1985; 102: 596-602. DOI: https://doi.org/10.7326/0003-4819-102-5-596
Bonadonna G. Lymphomas, Butterworth (in press).
Bonadonna G. Chemotherapy of malignant lymphomas. Semin One 1985; 12:(4) 1-4. Supp 6.
Cavalli F. VP-16 in the treatment of lymphomas. A report from the Swiss Group for Clinical Research (SAKK). Semin oncol 1985; 12;(1) 33-36. Supp 2.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
